S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Public Service Announcement: New National Emergency Incoming (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Better Than Oil Stocks (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Better Than Oil Stocks (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Public Service Announcement: New National Emergency Incoming (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Better Than Oil Stocks (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Better Than Oil Stocks (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Public Service Announcement: New National Emergency Incoming (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Better Than Oil Stocks (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Better Than Oil Stocks (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Public Service Announcement: New National Emergency Incoming (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Better Than Oil Stocks (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Better Than Oil Stocks (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024

United Therapeutics (UTHR) Stock Price, News & Analysis

$227.03
+9.43 (+4.33%)
(As of 02/23/2024 ET)
Today's Range
$218.41
$227.27
50-Day Range
$210.76
$246.40
52-Week Range
$204.44
$261.54
Volume
523,997 shs
Average Volume
328,913 shs
Market Capitalization
$10.68 billion
P/E Ratio
11.44
Dividend Yield
N/A
Price Target
$292.80

United Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.91 Rating Score
Upside/​Downside
29.0% Upside
$292.80 Price Target
Short Interest
Healthy
2.21% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.00
Upright™ Environmental Score
News Sentiment
0.92mentions of United Therapeutics in the last 14 days
Based on 38 Articles This Week
Insider Trading
Selling Shares
$8.97 M Sold Last Quarter
Proj. Earnings Growth
6.58%
From $22.04 to $23.49 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.99 out of 5 stars

Medical Sector

7th out of 941 stocks

Pharmaceutical Preparations Industry

2nd out of 431 stocks


UTHR stock logo

About United Therapeutics Stock (NASDAQ:UTHR)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

UTHR Stock Price History

UTHR Stock News Headlines

Clear Buy, Sell, or Hold Recommendation on any Stock, FREE
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
5 Fastest Growing Biotech Companies in the US
Beyond The Numbers: 4 Analysts Discuss United Therapeutics Stock
Clear Buy, Sell, or Hold Recommendation on any Stock, FREE
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
United Therapeutics Q4 Net Income Rises
United Therapeutics Corp
See More Headlines
Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
2/24/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:UTHR
CUSIP
91307C10
Employees
985
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$292.80
High Stock Price Target
$330.00
Low Stock Price Target
$215.00
Potential Upside/Downside
+29.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

Net Income
$727.30 million
Pretax Margin
54.75%

Debt

Sales & Book Value

Annual Sales
$2.33 billion
Cash Flow
$17.70 per share
Book Value
$127.35 per share

Miscellaneous

Free Float
41,120,000
Market Cap
$10.67 billion
Optionable
Optionable
Beta
0.52

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report














UTHR Stock Analysis - Frequently Asked Questions

Should I buy or sell United Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" UTHR shares.
View UTHR analyst ratings
or view top-rated stocks.

What is United Therapeutics' stock price target for 2024?

11 brokerages have issued twelve-month target prices for United Therapeutics' shares. Their UTHR share price targets range from $215.00 to $330.00. On average, they anticipate the company's share price to reach $292.80 in the next year. This suggests a possible upside of 29.0% from the stock's current price.
View analysts price targets for UTHR
or view top-rated stocks among Wall Street analysts.

How have UTHR shares performed in 2024?

United Therapeutics' stock was trading at $219.89 on January 1st, 2024. Since then, UTHR shares have increased by 3.2% and is now trading at $227.03.
View the best growth stocks for 2024 here
.

Are investors shorting United Therapeutics?

United Therapeutics saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 1,040,000 shares, a drop of 11.9% from the January 15th total of 1,180,000 shares. Based on an average daily trading volume, of 318,200 shares, the days-to-cover ratio is presently 3.3 days.
View United Therapeutics' Short Interest
.

When is United Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our UTHR earnings forecast
.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) released its earnings results on Wednesday, February, 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.28 by $0.08. The biotechnology company had revenue of $614.70 million for the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a net margin of 42.31% and a trailing twelve-month return on equity of 17.72%. The firm's revenue was up 25.1% on a year-over-year basis. During the same period in the previous year, the company posted $2.67 EPS.

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.95%), Avoro Capital Advisors LLC (6.08%), Dimensional Fund Advisors LP (1.20%), Nuveen Asset Management LLC (1.05%), Norges Bank (0.97%) and Palo Alto Investors LP (0.84%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek.
View institutional ownership trends
.

How do I buy shares of United Therapeutics?

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:UTHR) was last updated on 2/24/2024 by MarketBeat.com Staff